New diagnostic and prognostic markers of ventilator-associated pneumonia

Current Opinion in Critical Care

Volumn 12, Issue 5, 2006, Pages 446-451

  Chastre, Jean ^a   Luyt, Charles Edouard ^a   Trouillet, Jean Louis ^a   Combes, Alain ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antimicrobial therapy; Biologic marker; Diagnostic techniques; Healthcare associated pneumonia; Procalcitonin; Ventilator associated pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PROCALCITONIN;

ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BONE MARROW CELL; CELL TYPE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HUMAN; LUNG INFECTION; LUNG INJURY; MEDICAL LITERATURE; PROGNOSIS; RESPIRATORY TRACT INFECTION; REVIEW; SENSITIVITY ANALYSIS; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROID GLAND; VENTILATOR ASSOCIATED PNEUMONIA;

BIOLOGICAL MARKERS; CALCITONIN; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; HUMANS; MEMBRANE GLYCOPROTEINS; PNEUMONIA, VENTILATOR-ASSOCIATED; PROGNOSIS; PROTEIN PRECURSORS; RECEPTORS, IMMUNOLOGIC;

EID: 33748434925     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/01.ccx.0000244125.46871.44     Document Type: Review

References (61)

1. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
2. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
3. Muller B, Becker KL, Schachinger H, et al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000; 28:977-983.
4. Christ-Crain M, Muller B. Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Wkly 2005; 135:451-460. Review article carefully summarizing the pros and cons for using procalcitonin as a biologic marker of infection in the intensive care unit.
5. Becker KL, Nylen ES, White JC, et al. Clinical review 167: procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 2004; 89:1512-1525.
6. Weglohner W, Struck J, Fischer-Schulz C, et al. Isolation and characterization of serum procalcitonin from patients with sepsis. Peptides 2001; 22:2099-2103.
7. Muller B, White JC, Nylen ES, et al. Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001; 86:396-404.
8. Linscheid P, Seboek D, Nylen ES, et al. In vitro and in vivo calcitonin I gene expression in parenchymal cells: a novel product of human adipose tissue. Endocrinology 2003; 144:5578-5584.
9. Linscheid P, Seboek D, Schaer DJ, et al. Expression and secretion of procalcitonin and calcitonin gene-related peptide by adherent monocytes and by macrophage-activated adipocytes. Crit Care Med 2004; 32:1715-1721.
10. Dandona P, Nix D, Wilson MF, et al. Procalcitonin increase after endotoxin injection in normal subjects. J Clin Endocrinol Metab 1994; 79:1605-1608.
11. Becker KL, Nylen ES, Snider RH, et al. Immunoneutralization of procalcitonin as therapy of sepsis. J Endotoxin Res 2003; 9:367-374.
12. Nylen ES, Whang KT, Snider RH Jr, et al. Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 1998; 26:1001-1006.
13. Wagner KE, Martinez JM, Vath SD, et al. Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 2002; 30:2313-2321.
14. Harbarth S, Holeckova K, Froidevaux C, et al. Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001; 164:396-402.
15. Clec'h C, Fosse JP, Karoubi P, et al. Differential diagnostic value of procalcitonin in surgical and medical patients with septic shock. Crit Care Med 2006; 34:102-107.
16. Hausfater P, Garric S, Ayed SB, et al. Usefulness of procalcitonin as a marker of systemic infection in emergency department patients: a prospective study. Clin Infect Dis 2002; 34:895-901.
17. Luzzani A, Polati E, Dorizzi R, et al. Comparison of procalcitonin and Creactive protein as markers of sepsis. Crit Care Med 2003; 31:1737-1741.
18. Simon L, Gauvin F, Amre DK, et al. Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 2004; 39:206-217.
19. Uzzan B, Cohen R, Nicolas P, et al. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 2006 [epub ahead of print]. Recent meta-analysis of 25 studies that evaluated the diagnostic accuracy of procalcitonin in the intensive care unit, confirming that the summary ROC curve for procalcitonin was better than for CRP, the former test showing better accuracy.
20. Mimoz O, Benoist JF, Edouard AR, et al. Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome. Intensive Care Med 1998; 24:185-188.
21. Meisner M, Rauschmayer C, Schmidt J, et al. Early increase of procalcitonin after cardiovascular surgery in patients with postoperative complications. Intensive Care Med 2002; 28:1094-1102.
22. Meisner M, Tschaikowsky K, Hutzler A, et al. Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 1998; 24:680-684.
23. Adamik B, Kubler-Kielb J, Golebiowska B, et al. Effect of sepsis and cardiac surgery with cardiopulmonary bypass on plasma level of nitric oxide metabolites, neopterin, and procalcitonin: correlation with mortality and postoperative complications. Intensive Care Med 2000; 26:1259-1267.
24. Aouifi A, Piriou V, Bastien O, et al. Usefulness of procalcitonin for diagnosis of infection in cardiac surgical patients. Crit Care Med 2000; 28:3171-3176.
25. Arkader R, Troster EJ, Abellan DM, et al. Procalcitonin and C-reactive protein kinetics in postoperative pediatric cardiac surgical patients. J Cardiothorac Vasc Anesth 2004; 18:160-165.
26. Brunkhorst FM, Eberhard OK, Brunkhorst R. Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 1999; 27:2172-2176.
27. Stiletto RJ, Baacke M, Gotzen L, et al. Procalcitonin versus interleukin-6 levels in bronchoalveolar lavage fluids of trauma victims with severe lung contusion. Crit Care Med 2001; 29:1690-1693.
28. Eberhard OK, Langefeld I, Kuse ER, et al. Procalcitonin in the early phase after renal transplantation-will it add to diagnostic accuracy? Clin Transplant 1998; 12:206-211.
29. de Werra I, Jaccard C, Corradin SB, et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997; 25:607-613.
30. Nylen ES, Al Arifi A, Becker KL, et al. Effect of classic heatstroke on serum procalcitonin. Crit Care Med 1997; 25:1362-1365.
31. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004; 363:600-607.
32. Soderquist B, Jones I, Fredlund H, Vikerfors T. Bacterial or crystal-associated arthritis? Discriminating ability of serum inflammatory markers. Scand J Infect Dis 1998; 30:591-596.
33. van Dissel JT. Procalcitonin: what should be its role in the clinical management of febrile patients admitted to the hospital? Clin Infect Dis 2003; 36:824-825.
34. Mueller C, Huber P, Laifer G, et al. Procalcitonin and the early diagnosis of infective endocarditis. Circulation 2004; 109:1707-1710.
35. Snider RH Jr, Nylen ES, Becker KL. Procalcitonin and its component peptides in systemic inflammation: immunochemical characterization. J Invest Med 1997; 45:552-560.
36. Nylen ES, Snider RH Jr, Thompson KA, et al. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996; 312:12-18.
37. Boussekey N, Leroy O, Alfandari S, et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med 2006; 32:469-472.
38. Duflo F, Debon R, Monneret G, et al. Alveolar and serum procalcitonin: diagnostic and prognostic value in ventilator-associated pneumonia. Anesthesiology 2002; 96:74-79.
39. Gibot S, Cravoisy A. Soluble form of the triggering receptor expressed on myeloid cells-1 as a marker of microbial infection. Clin Med Res 2004; 2:181-187.
40. Luyt CE, Guerin V, Combes A, et al. Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia. Am J Respir Crit Care Med 2005; 171:48-53. The value of procalcitonin kinetics as a prognostic marker during VAP was investigated in a prospective, observational study of 63 patients with microbiologically proven VAP. To predict unfavorable outcome, a procalcitonin cut-off value of 0.5 ng/ml on day 7 had a sensitivity of 90% and a specificity of 88%, leading the authors to postulate that procalcitonin may provide an opportunity to change the treatment strategy early in the course of VAP.
41. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-682.
42. Combes A, Figliolini C, Trouillet JL, et al. Factors predicting ventilator-associated pneumonia recurrence. Crit Care Med 2003; 31:1102-1107.
43. Dennesen PJ, van der Ven AJ, Kessels AG, et al. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-1375.
44. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia - a randomized trial. Am J Respir Crit Care Med 2006 [epub ahead of print]. Using serial procalcitonin results as a guide to therapy in patients with community-acquired pneumonia, the authors were able to demonstrate that such a decision tree significantly reduced the duration of antibiotic treatment from a median of 12 days to 5 days without any adverse effects on outcome.
45. Muller B, Becker KL. Procalcitonin: how a hormone became a marker and mediator of sepsis. Swiss Med Wkly 2001; 131:595-602.
46. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol 2000; 164:4991-4995.
47. Bouchon A, Facchetti F, Weigand MA, Colonna M. TREM-1 amplifies inflammation and is a crucial mediator of septic shock. Nature 2001; 410:1103-1107.
48. Radsak MP, Salih HR, Rammensee HG, Schild H. Triggering receptor expressed on myeloid cells-1 in neutrophil inflammatory responses: differential regulation of activation and survival. J Immunol 2004; 172:4956-4963.
49. Gibot S, Kolopp-Sarda MN, Bene MC, et al. A soluble form of the triggering receptor expressed on myeloid cells-1 modulates the inflammatory response in murine sepsis. J Exp Med 2004; 200:1419-1426.
50. Gibot S, Kolopp-Sarda MN, Bene MC, et al. Plasma level of a triggering receptor expressed on myeloid cells-1: its diagnostic accuracy in patients with suspected sepsis. Ann Intern Med 2004; 141:9-15.
51. Gibot S, Cravoisy A, Levy B, et al. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med 2004; 350:451-458.
52. Pugin J, Auckenthaler R, Mili N, et al. Diagnosis of ventilator- associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic 'blind' bronchoalveolar lavage fluid. Am Rev Respir Dis 1991; 143:1121-1129.
53. Richeldi L, Mariani M, Losi M, et al. Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections. Eur Respir J 2004; 24:247-250.
54. Determann RM, Millo JL, Gibot S, et al. Serial changes in soluble triggering receptor expressed on myeloid cells in the lung during development of ventilator-associated pneumonia. Intensive Care Med 2005; 31:1495-1500.
55. Routsi C, Giamarellos-Bourboulis EJ, Antonopoulou A, et al. Does soluble triggering receptor expressed on myeloid cells-1 play any role in the pathogenesis of septic shock? Clin Exp Immunol 2005; 142:62-67.
56. Pugin J, Auckenthaler R, Delaspre O, et al. Rapid diagnosis of gram negative pneumonia by assay of endotoxin in bronchoalveolar lavage fluid. Thorax 1992; 47:547-549.
57. Nys M, Ledoux D, Canivet JL, et al. Correlation between endotoxin level and bacterial count in bronchoalveolar lavage fluid of ventilated patients. Crit Care Med 2000; 28:2825-2830.
58. Kollef MH, Eisenberg PR, Ohlendorf MF, Wick MR. The accuracy of elevated concentrations of endotoxin in bronchoalveolar lavage fluid for the rapid diagnosis of gram-negative pneumonia. Am J Respir Crit Care Med 1996; 154:1020-1028.
59. Flanagan PG, Jackson SK, Findlay G. Diagnosis of gram negative, ventilator associated pneumonia by assaying endotoxin in bronchial lavage fluid. J Clin Pathol 2001; 54:107-110.
60. Froon AH, Bonten MJ, Gaillard CA, et al. Prediction of clinical severity and outcome of ventilator-associated pneumonia. Comparison of simplified acute physiology score with systemic inflammatory mediators. Am J Respir Crit Care Med 1998; 158:1026-1031.
61. Duflo F, Debon R, Goudable J, et al. Alveolar and serum oxidative stress in ventilator-associated pneumonia. Br J Anaesth 2002; 89:231-236.